Back to search
FDAFDA · Food and drugs·Recall number D-0918-2023

Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382 210, India, NDC 16729-275-67.

Published July 19, 2023 · Recall initiated: July 3, 2023

Summary

FDA records drug Class II recall D-0918-2023, published July 19, 2023 and initiated July 3, 2023. Recalling firm: Accord Healthcare, Inc.; Status: Terminated; Reported quantity: 1680 vials; Lot: Lot #: M2212070 Exp. date 08/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Particulate matter identified as fiber.

What to do

Voluntary: Firm initiated · Letter

Get an email if BIVALIRUDIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BIVALIRUDIN
Manufacturer
Accord Healthcare, Inc.
Distributor
Nationwide within the United States
UPC
0316729275033
Lot
Lot #: M2212070 Exp. date 08/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382 210, India, NDC 16729-275-67. recalled?

Yes. FDA published recall D-0918-2023 on July 19, 2023. Reported hazard: Presence of Particulate Matter: Particulate matter identified as fiber.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BIVALIRUDIN. UPC: 0316729275033.